A pilot study conducted by Vaaji, in collaboration with the Penn Artificial Intelligence and Technology Collaboratory (PennAITech) at the University of Pennsylvania, has demonstrated 100% technical accuracy in monitoring transdermal patch status. The findings validate Vaaji's proprietary smart patch system as a robust tool with the potential to significantly improve safety in transdermal drug delivery, particularly for patients with Alzheimer's disease, Parkinson's, and chronic pain.
The study, part of the AI/Tech + Aging (A2) Collective funded by the National Institute on Aging, enrolled 51 healthy volunteers using placebo patches to evaluate the system's detection capabilities against manual oversight. Results confirmed perfect agreement between Vaaji's remote monitoring data and site investigator records, matching the gold standard of direct human supervision. The system also successfully identified simulated 'patch stacking'—the dangerous practice of applying a new patch without removing the old one—in real time. This validates the core technology required to prevent overdose events in future clinical applications.
Transdermal patches are a vital delivery mechanism for medications treating Alzheimer's (such as rivastigmine), Parkinson's, and pain management. However, in real-world scenarios, patients or overwhelmed caregivers may accidentally apply a new patch without removing the old one or forget applications entirely, leading to ineffective treatment or potentially life-threatening overdoses. Vaaji's solution transforms standard passive patches into 'smart' therapeutics by leveraging advanced Internet of Things (IoT) sensors and artificial intelligence to provide real-time visibility into medication adherence.
Patrick Mercier, Professor of Electrical and Computer Engineering at UCSD and Chief Technical Advisor at Vaaji, stated: 'This study provides the first real-world evidence that our smart patch platform can deliver perfect accuracy in detecting patch application errors—a critical step toward enhancing patient safety in Alzheimer's care. We have proven that the underlying technology is robust, scalable, and ready for further development.'
William Z. Potter, MD, PhD, co-Principal Investigator and Chief Scientific Advisor at Vaaji, added: 'The 100% agreement between remote monitoring and site investigator records is a landmark result for this early-stage development. It demonstrates that our system has the potential to match human oversight, paving the way for safer, smarter home care solutions.'
The data from this pilot study will inform Vaaji's clinical and regulatory strategy as the company advances toward broader clinical trials involving active therapeutics. The company aims to establish its smart monitoring platform as a new safety standard for high-risk transdermal medications. For more information, visit www.vaaji.io.
The project described is supported by the National Institute on Aging of the National Institutes of Health under Award Number 1-P30-AG-073105-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
